A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05262023

Recruitment Status : Active, not recruiting

First Posted : March 2, 2022

Last Update Posted : January 9, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Takeda

Information provided by (Responsible Party):

Denali Therapeutics Inc.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	November 2025
Estimated Study Completion Date :	November 2025

To Top